Deep Dive, Drug Development

Optimizing clinical outcomes for challenging molecules with lipid-based drug delivery

Pictured: OptiShell. All images courtesy of Catalent Pharma Solutions. © 2017 Catalent, Inc. All rights reserved

Implementing a bioavailability enhancing formulation approach can positively impact safety, efficacy, and patient adherence, leading to successful clinical outcomes.  This article takes an in-depth look at how lipid-based drug delivery systems (LBDDS) can be used as a bioavailability enhancing technology, as well as the softgel dosage form for their delivery, in order to achieve successful clinical outcomes.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 44,000+ biopharma executives who read Endpoints News every day.

Sponsored by Catalent Pharma Solutions.
Access is subject to the terms in our Privacy Policy.